Liquid chromatography-tandem mass spectrometric assay for the mutated BRAF inhibitor dabrafenib in mouse plasma

Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences

Volumn 925, Issue , 2013, Pages 124-128

  Sparidans, Rolf W ^a   Durmus, Selvi ^b   Schinkel, Alfred H ^b   Schellens, Jan H M ^a,b   Beijnen, Jos H ^a,b,c  

^a UTRECHT UNIVERSITY   (Netherlands)

^b NETHERLANDS CANCER INSTITUTE   (Netherlands)

^c SLOTERVAART HOSPITAL   (Netherlands)

Author keywords

Dabrafenib; LC MS MS; Mutated BRAF inhibitor; Plasma

Indexed keywords

ANALYTICAL CONDITIONS; CHROMATOGRAPHIC SYSTEMS; DABRAFENIB; ELECTROSPRAY INTERFACES; LC-MS/MS; MUTATED BRAF INHIBITOR; SELECTED REACTION MONITORING; TRIPLE-QUADRUPOLE MASS SPECTROMETER;

CALIBRATION; ELECTROSPRAY IONIZATION; LIQUID CHROMATOGRAPHY; MAMMALS; MASS SPECTROMETRY; POSITIVE IONS;

PLASMAS;

B RAF KINASE; DABRAFENIB;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CALIBRATION; CHEMICAL STRUCTURE; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG DETERMINATION; DRUG STABILITY; ELECTROSPRAY; LIQUID CHROMATOGRAPHY; MEASUREMENT ACCURACY; MOUSE; MUTATION; NONHUMAN; PRECIPITATION; PRIORITY JOURNAL; QUADRUPOLE MASS SPECTROMETRY; TANDEM MASS SPECTROMETRY;

ANIMALS; CHROMATOGRAPHY, LIQUID; FEMALE; IMIDAZOLES; LINEAR MODELS; MICE; OXIMES; PROTO-ONCOGENE PROTEINS B-RAF; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY; SPECTROMETRY, MASS, ELECTROSPRAY IONIZATION; TANDEM MASS SPECTROMETRY;

MUS;

EID: 84875653035     PISSN: 15700232     EISSN: 1873376X     Source Type: Journal    
DOI: 10.1016/j.jchromb.2013.02.025     Document Type: Article

References (15)

1. Puzanov I., Flaherty K.T. Semin. Cutan. Med. Surg. 2010, 29:196.
2. Long G.V., Trefzer U., Davies M.A., Kefford R.F., Ascierto P.A., Chapman P.B., et al. Lancet Oncol. 2012, 13:1087.
3. Hauschild A., Grob J.J., Demidov L.V., Jouary T., Gutzmer R., Millward M., et al. Lancet 2012, 380:358.
4. U.S. National Institutes of Health, 2012 (accessed 10.12.12). http://clinicaltrials.gov/ct2/results%3Fterm=dabrafenib%26Search=Search.
5. GlaxoSmithKline, 2009 (accessed 10.12.12). http://www.google.nl/url%3Fq=http%3A//download.gsk-clinicalstudyregister.com/files/3d23d07b-74c9-4f0f-8c2c-cc4c64db9e97%26sa=U%26ei=kZvFUNn2GoeP0AXL6YFo%26ved=0CBYQFjAA%26usg=AFQjCNGaJ0iAUkylHAVK1lvIGfDEnuDzSw.
6. Center for Drug Evaluation and Research of the U.S. Department of Health and Human Services Food and Drug Administration, 2001 (accessed 10.12.12). http://www.fda.gov/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm064964.htm.
7. Shah V.P., Midha K.K., Findlay J.W.A., Hill H.M., Hulse J.D., McGilveray I.J., et al. Pharm. Res. 2000, 17:1551.
8. Viswanathan C.T., Bansal S., Booth B., DeStefano A.J., Rose M.J., Sailstad J., et al. Pharm. Res. 2007, 24:1962.
9. Sparidans R.W., Iusuf D., Schinkel A.H., Schellens J.H., Beijnen J.H. J. Chromatogr. B: Anal. Technol. Biomed. Life Sci. 2009, 877:4090.
10. Trufelli H., Palma P., Famiglini G., Cappiello A. Mass Spectrom. Rev. 2010, 30:491.
11. Blanchard J. J. Chromatogr. 1981, 226:455.
12. Sparidans R.W., Durmus S., Xu N., Schinkel A.H., Schellens J.H., Beijnen J.H. J. Chromatogr. B: Anal. Technol. Biomed. Life Sci. 2012, 895-896:174.
13. Sparidans R.W., Durmus S., Xu N., Schinkel A.H., Schellens J.H., Beijnen J.H. J. Chromatogr. B: Anal. Technol. Biomed. Life Sci. 2012, 895-896:169.
14. Sparidans R.W., Tang S.C., Nguyen L.N., Schinkel A.H., Schellens J.H., Beijnen J.H. J. Chromatogr. B: Anal. Technol. Biomed. Life Sci. 2012, 905:150.
15. European Medicines Agency, 2009 (accessed 10.12.12). http://www.ema.europa.eu/pdfs/human/ewp/19221709en.pdf.